Evidence map›Paper›PMID 33765237›Full record

ReviewNeurotoxicity research2021

Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.

Mohamed El-Gamal, Mohamed Salama, Lyndsey E Collins-Praino, Irina Baetu, Ahmed M Fathalla, Amira M Soliman, Wael Mohamed, Ahmed A Moustafa

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurotoxicity research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Mohamed El-GamalToxicology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. doctorelgamal@mans.edu.eg.
Mohamed SalamaToxicology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Lyndsey E Collins-PrainoUniversity of Adelaide, Adelaide, Australia.
Irina BaetuUniversity of Adelaide, Adelaide, Australia.
Ahmed M FathallaDepartment of Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Amira M SolimanDepartment of Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Wael MohamedClinical Pharmacology Department, Faculty of Medicine, Menoufia University, Mansoura, Egypt.
Ahmed A MoustafaSchool of Social Sciences and Psychology and Marcs Institute for Brain and Behaviour, Western Sydney University, Sydney, NSW, Australia.
Suez Canal University · EGUniversity of Adelaide · AUInternational Islamic University Malaysia · MYMansoura University · EGTrinity College Dublin · IEUniversity of Johannesburg · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by cardinal motor impairments, including akinesia and tremor, as well as by a host of non-motor symptoms, including both autonomic and cognitive dysfunction. PD is associated with a death of nigral dopaminergic neurons, as well as the pathological spread of Lewy bodies, consisting predominantly of the misfolded protein alpha-synuclein. To date, only symptomatic treatments, such as levodopa, are available, and trials aiming to cure the disease, or at least halt its progression, have not been successful. Wong et al. (2019) suggested that the lack of effective therapy against neurodegeneration in PD might be attributed to the fact that the molecular mechanisms standing behind the dopaminergic neuronal vulnerability are still a major scientific challenge. Understanding these molecular mechanisms is critical for developing effective therapy. Thirty-five years ago, Calne and William Langston (1983) raised the question of whether biological or environmental factors precipitate the development of PD. In spite of great advances in technology and medicine, this question still lacks a clear answer. Only 5-15% of PD cases are attributed to a genetic mutation, with the majority of cases classified as idiopathic, which could be linked to exposure to environmental contaminants. Rodent models play a crucial role in understanding the risk factors and pathogenesis of PD. Additionally, well-validated rodent models are critical for driving the preclinical development of clinically translatable treatment options. In this review, we discuss the mechanisms, similarities and differences, as well as advantages and limitations of different neurotoxin-induced rat models of PD. In the second part of this review, we will discuss the potential future of neurotoxin-induced models of PD. Finally, we will briefly demonstrate the crucial role of gene-environment interactions in PD and discuss fusion or dual PD models. We argue that these models have the potential to significantly further our understanding of PD.

Indexed as

Disease Models, AnimalAnimalsDopaminergic NeuronsHumansNeurotoxinsOxidopamineParaquatParkinsonian DisordersRodentiaSubstantia NigraNeurotoxinsOxidopamineParaquatAnimal modelsDopamineEpigeneticsParkinsonianPesticidesToxins

Identifiers

PMID33765237
OpenAlexW3139444129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.